PetLife Pharmaceuticals, Inc.: 10-Q filed 2012-07-23
What PetLife Pharmaceuticals, Inc. reported in its quarterly report filed 2012-07-23 (fiscal Q3 2012): 18 published measures, 45 facts as tagged in accession 0001096906-12-001843.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-07-23
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001096906-12-001843 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PetLife Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 776,510 | USD | |
| At 2011-08-31 | 795,303 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | -15,199 | USD | |
| At 2011-08-31 | 307,569 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-03-01 to 2012-05-31 | -163,011 | USD | 92 |
| 2011-09-30 to 2012-05-31 | -805,446 | USD | 245 |
| 2010-11-09 to 2012-05-31 | -1,271,855 | USD | 570 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-09-01 to 2012-05-31 | -349,854 | USD | 274 |
| 2010-11-09 to 2012-05-31 | -490,905 | USD | 570 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-09-01 to 2012-05-31 | 36,971 | USD | 274 |
| 2010-11-09 to 2012-05-31 | 206,367 | USD | 570 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-09-01 to 2012-05-31 | 331,251 | USD | 274 |
| 2010-11-09 to 2012-05-31 | 697,605 | USD | 570 |
| 2010-11-09 to 2011-05-31 | 250 | USD | 204 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-09-01 to 2012-05-31 | -36,971 | USD | 274 |
| 2010-11-09 to 2012-05-31 | -206,367 | USD | 570 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 766,367 | USD | |
| At 2011-08-31 | 729,396 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-09-01 to 2012-05-31 | 139,552 | USD | 274 |
| 2010-11-09 to 2012-05-31 | -484,969 | USD | 570 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-03-01 to 2012-05-31 | -219,940 | USD | 92 |
| 2011-09-30 to 2012-05-31 | -1,074,585 | USD | 245 |
| 2010-11-09 to 2012-05-31 | -1,961,202 | USD | 570 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 10,333 | USD | |
| At 2011-08-31 | 65,907 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-03-01 to 2012-05-31 | 8,948 | USD | 92 |
| 2011-09-30 to 2012-05-31 | 20,102 | USD | 245 |
| 2010-11-09 to 2012-05-31 | 25,339 | USD | 570 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 1,056,467 | USD | |
| At 2011-08-31 | 463,061 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-03-01 to 2012-05-31 | 172,092 | USD | 92 |
| 2011-09-30 to 2012-05-31 | 914,611 | USD | 245 |
| 2010-11-09 to 2012-05-31 | 1,745,205 | USD | 570 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 2,155,591 | shares | |
| At 2011-08-31 | 1,959,888 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | 1,485,010 | USD | |
| At 2011-08-31 | 1,002,643 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-05-31 | -279,768 | USD | |
| At 2011-09-27 | 332,242 | USD | |
| At 2011-08-31 | 332,242 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-03-01 to 2012-05-31 | -228,888 | USD | 92 |
| 2011-09-30 to 2012-05-31 | -1,094,687 | USD | 245 |
| 2011-09-28 to 2012-05-31 | -1,094,687 | USD | 247 |
| 2011-09-01 to 2012-05-31 | -1,094,687 | USD | 274 |
| 2010-11-09 to 2012-05-31 | -1,724,748 | USD | 570 |
Inspect the source
- Entity
- PetLife Pharmaceuticals, Inc. / CIK 0001354591
- Captured
- SEC response SHA-256
41a0ceb8f85d25ccf92688c1e58fdda5b8df53bc4f4e1ac81b38afabe0cc1efa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001354591.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))